{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000208","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2022-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.417615+00:00","generated_at":"2026-06-27T07:22:03.658977+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Charles River Q4 rev $905.1M (+14.4%); reaffirms 2022 guidance with non-GAAP EPS $11.50-$11.75","bullets":["Q4 GAAP EPS $2.67 vs $2.81 prior year (-5%); non-GAAP EPS $2.49 vs $2.39 (+4.2%).","Full-year 2021 revenue $3.54B (+21.1%); organic growth 15.1%; non-GAAP EPS $10.32 (+26.9%).","RMS segment organic growth 13.3%; DSA organic growth 6.7%; Manufacturing organic growth 21.2%.","2022 guidance: organic revenue growth 12.5-14.5%; non-GAAP EPS $11.50-$11.75; free cash flow ~$450M.","GAAP net income Q4 $137.6M vs $143.2M; full-year $391M vs $364.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000208","json":"https://secwatch.observer/filing/0001157523-22-000208.json","markdown":"https://secwatch.observer/filing/0001157523-22-000208.md","text":"https://secwatch.observer/filing/0001157523-22-000208.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000115752322000208/0001157523-22-000208-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000115752322000208/a52579962.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T07:22:03.658977+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}